Phase 1 Trial of KL0011034 Continuous Infusion Registered, Not Yet Recruiting

A new Phase 1 clinical trial listing related to corticotropin research was registered on September 25, 2026. The study, titled "Safety, Pharmacokinetics, and Pharmacodynamics of Continuous KL0011034 Infusion in Healthy Chinese Adults," carries the identifier NCT07841626. Its current status is listed as not yet recruiting. The trial is designated as Phase 1, indicating an early stage study focused on safety, pharmacokinetics, and pharmacodynamics in a healthy adult population based in China. No enrollment has begun and no results have been posted at this time. The listing does not include information on trial design details beyond the stated title and phase. As the study has not started recruiting, no participant data, safety findings, or outcome measures are currently available for review. Interested parties can monitor the official registration for updates as the trial status changes. This entry reflects only the administrative registration of the study and does not represent findings, conclusions, or safety determinations regarding corticotropin or KL0011034. For background on corticotropin, including its approved regulatory status and general profile, readers can consult the compound overview.